Avalyn Pharma insider reports stock option holdings
Avalyn Pharma Inc. executive Carlson Douglas R filed an initial Form 3 showing stock option holdings in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Avalyn Pharma Inc. executive Carlson Douglas R filed an initial Form 3 showing stock option holdings in the company. He holds options to acquire 83,576 shares of common stock at an exercise price of $4.81 per share, expiring on September 10, 2035, and options on 270,498 shares at $4.62 per share, expiring on June 10, 2034.
For the $4.81 options, 25% of the underlying shares vested on May 1, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. For the $4.62 options, 25% vest on May 29, 2026, with the balance also vesting in 36 monthly installments, contingent on his continued service.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Carlson Douglas R
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 354,074 contracts (Direct)
Footnotes (2)
- F1. 25% of the shares underlying this option vested and became exercisable on May 1, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F2. 25% of the shares underlying this option vest and become exercisable on May 29, 2026, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option exercise price: $4.81 per share
Underlying shares: 83,576 shares
Option exercise price: $4.62 per share
+3 more
6 metrics
Option exercise price
$4.81 per share
Stock option on 83,576 underlying common shares
Underlying shares
83,576 shares
Common stock underlying $4.81 options, expiring September 10, 2035
Option exercise price
$4.62 per share
Stock option on 270,498 underlying common shares
Underlying shares
270,498 shares
Common stock underlying $4.62 options, expiring June 10, 2034
Initial vesting date
May 1, 2025
25% vesting for $4.81 options; remaining 75% over 36 months
Initial vesting date
May 29, 2026
25% vesting for $4.62 options; remaining 75% over 36 months
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 4.8100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2035-09-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"25% of the shares underlying this option vested and became exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 3 regulatory
"initial Form 3 showing stock option holdings"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Avalyn Pharma (AVLN) Form 3 filing for Carlson Douglas R show?
The Form 3 shows Carlson Douglas R’s initial derivative holdings in Avalyn Pharma, including stock options to buy 83,576 shares at $4.81 and 270,498 shares at $4.62, with specified vesting schedules and long-dated expiration dates in 2034 and 2035.
What are the vesting terms of Carlson Douglas R’s Avalyn Pharma (AVLN) options?
For the $4.81 options, 25% of the underlying shares vested on May 1, 2025, with the remaining 75% vesting in 36 equal monthly installments. For the $4.62 options, 25% vest on May 29, 2026, with the rest vesting over 36 monthly installments, all requiring continued service.
When do Carlson Douglas R’s Avalyn Pharma (AVLN) stock options expire?
The options with a $4.81 exercise price expire on September 10, 2035, and the options with a $4.62 exercise price expire on June 10, 2034. These long-dated expirations give a multi‑year window during which vested options can potentially be exercised.
Does the Avalyn Pharma (AVLN) Form 3 indicate any recent buying or selling by Carlson Douglas R?
The Form 3 reflects holdings, not recent trades, and shows no buy or sell transactions. It lists existing stock option positions, their exercise prices, expiration dates, and vesting terms, establishing a baseline of Carlson Douglas R’s derivative ownership in Avalyn Pharma.
AI-generated analysis. How Rhea-AI works. Not financial advice.
